Please select the outcome measures that correspond to the clinical trial below.
Title: GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.


Options:
A: Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase. (Week 52)
B: SLE Responder Index (SRI) Response Rate at Week 52 (Baseline, 52 weeks)
C: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) (Up to Week 440); AE Rates by System Organ Class (SOC) During the Study (Up Week 440); SAE Rates by System Organ Class (SOC) During the Study (Up to Week 440); Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points (Up to Week 440); Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points (Up to Week 440); Change From Baseline in Erythrocytes at the Indicated Time Points (Up to Week 440); Change From Baseline in Hematocrit at the Indicated Time Points (Up to Week 440); Change From Baseline in Hemoglobin at the Indicated Time Points (Up to Week 440); Change From Baseline in Albumin and Protein at the Indicated Time Points (Up to Week 440); Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points (Up to Week 440); Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points (Up to Week 440); Change From Baseline in Creatinine Clearance at the Indicated Time Points (Up to Week 440); Change From Baseline in BUN/Creatinine at the Indicated Time Points (Up to Week 440); Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points (Up to Week 432); Number of Participants With the Indicated Immunogenic Response (Up to Week 440); Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points. (Up to Week 432); Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points. (Up to Week 440); Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval. (Up to Week 440)
D: Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs) (Approximately up to 13 years); Adverse Event (AE) Rates by System Organ Class (SOC) During the Study (Approximately up to 13 years); SAE Rates by System Organ Class (SOC) During the Study (Approximately up to 13 years); Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Erythrocytes at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Hematocrit at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Hemoglobin at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Albumin and Protein at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in BUN/Creatinine at the Indicated Time Points (Baseline and approximately up to 13 years); Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points (Baseline and approximately up to 13 years)

Answer: A